Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.

The pharmacokinetics and bioavailability of adefovir [9-[2-(phosphonomethoxy)ethyl]adenine] were examined at two dose levels in three phase I/II studies in 28 human immunodeficiency type 1-infected patients. The concentrations of adefovir in serum following the intravenous infusion of 1.0 or 3.0 mg/...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrob Agents Chemother
Hlavní autoři:	Cundy, K C, Barditch-Crovo, P, Walker, R E, Collier, A C, Ebeling, D, Toole, J, Jaffe, H S
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 1995
Témata:	Research Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162955/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8585716/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.11.2401
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!